Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue-Focus on RAGE and IDO1.
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm
/ genetics
Biomarkers, Tumor
/ genetics
Case-Control Studies
Endometrial Neoplasms
/ genetics
Endometrium
/ immunology
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Immunomodulation
Indoleamine-Pyrrole 2,3,-Dioxygenase
/ genetics
Kynurenine
/ metabolism
Middle Aged
Mitogen-Activated Protein Kinases
/ genetics
Primary Cell Culture
Prognosis
Receptor, ErbB-2
/ genetics
Tumor Microenvironment
/ immunology
RAGE
endometrium
indoleamine 2,3-dioxygenase 1
kynurenine
primary cell culture
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
25 04 2021
25 04 2021
Historique:
received:
12
03
2021
revised:
16
04
2021
accepted:
20
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
9
11
2021
Statut:
epublish
Résumé
Immune modulatory factors like indoleamine 2,3-dioxygenase 1 (IDO1) generating kynurenine (Kyn) and receptor for advanced glycation end-products (RAGE) contribute to endometrial and cancer microenvironment. Using adequate experimental models is needed to learn about the significance of these molecular factors in endometrial biology. In this paper we study IDO1 activity and RAGE expression in the in vitro cultured primary human endometrial cells derived from cancerous and noncancerous tissue. The generated primary cell cultures from cancer and noncancerous endometrial tissues were characterized using immunofluorescence and Western Blot for expression of endometrial and cancer markers. IDO1 activity was studied by Kyn quantification with High Performance Liquid Chromatography with Diode Array Detector. The primary cultures of endometrial cells were obtained with 80% success rate and no major genetic aberrations. The cells retained in vitro expression of markers (mucin MUC1 and HER2) or immunomodulatory factors (RAGE and IDO1). Increased Kyn secretion was associated with cancer endometrial cell culture in contrast to the control one. Primary endometrial cells express immune modulatory factors RAGE and IDO1 in vitro associated with cancer phenotype of endometrium.
Sections du résumé
BACKGROUND
Immune modulatory factors like indoleamine 2,3-dioxygenase 1 (IDO1) generating kynurenine (Kyn) and receptor for advanced glycation end-products (RAGE) contribute to endometrial and cancer microenvironment. Using adequate experimental models is needed to learn about the significance of these molecular factors in endometrial biology. In this paper we study IDO1 activity and RAGE expression in the in vitro cultured primary human endometrial cells derived from cancerous and noncancerous tissue.
METHODS
The generated primary cell cultures from cancer and noncancerous endometrial tissues were characterized using immunofluorescence and Western Blot for expression of endometrial and cancer markers. IDO1 activity was studied by Kyn quantification with High Performance Liquid Chromatography with Diode Array Detector.
RESULTS
The primary cultures of endometrial cells were obtained with 80% success rate and no major genetic aberrations. The cells retained in vitro expression of markers (mucin MUC1 and HER2) or immunomodulatory factors (RAGE and IDO1). Increased Kyn secretion was associated with cancer endometrial cell culture in contrast to the control one.
CONCLUSIONS
Primary endometrial cells express immune modulatory factors RAGE and IDO1 in vitro associated with cancer phenotype of endometrium.
Identifiants
pubmed: 33922995
pii: cells10051013
doi: 10.3390/cells10051013
pmc: PMC8145962
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
IDO1 protein, human
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Kynurenine
343-65-7
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
MOK protein, human
EC 2.7.11.22
Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Narodowe Centrum Badań i Rozwoju
ID : STRATEGMED II/269364/5NCBR/2015
Organisme : European Regional Development Fund
ID : POPW.01.03.00-06-003/09-00
Références
Breast Cancer Res Treat. 2015 Sep;153(2):311-21
pubmed: 26283301
Endocrinology. 2007 Aug;148(8):3814-26
pubmed: 17510236
Hum Reprod. 2006 Sep;21(9):2238-45
pubmed: 16807280
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Annu Rev Immunol. 2010;28:367-88
pubmed: 20192808
Am J Pathol. 2003 Dec;163(6):2259-69
pubmed: 14633600
J Immunother Cancer. 2019 Oct 29;7(1):280
pubmed: 31665084
Sci Rep. 2017 Aug 18;7(1):8803
pubmed: 28821813
Gynecol Endocrinol. 2003 Feb;17(1):37-44
pubmed: 12724017
Stem Cells Dev. 2013 Mar 15;22(6):964-74
pubmed: 23216285
BMC Cancer. 2016 Feb 12;16:93
pubmed: 26873694
F1000Res. 2019 Jun 12;8:
pubmed: 31231511
Pharmacol Ther. 2019 Apr;196:105-116
pubmed: 30521884
J Biol Chem. 2011 Oct 7;286(40):35061-70
pubmed: 21844192
Vet Med Sci. 2018 Nov;4(4):326-332
pubmed: 29984902
J Reprod Immunol. 2017 Nov;124:44-53
pubmed: 29055791
Differentiation. 2017 Nov - Dec;98:62-69
pubmed: 29156254
Semin Cancer Biol. 2018 Apr;49:44-55
pubmed: 28712719
Hum Reprod. 2014 Aug;29(8):1730-8
pubmed: 24939955
Immunobiology. 2013 May;218(5):790-7
pubmed: 23182709
Reproduction. 2016 Sep;152(3):225-33
pubmed: 27340235
Br J Cancer. 2018 Feb 6;118(3):378-387
pubmed: 29169184
Oncotarget. 2016 May 31;7(22):32796-809
pubmed: 27092881
Cancer Res. 2015 Mar 15;75(6):974-85
pubmed: 25572331
Clin Chim Acta. 2019 Feb;489:225-232
pubmed: 30107158
Trends Endocrinol Metab. 2018 Jul;29(7):481-491
pubmed: 29705365
Immunity. 2013 Mar 21;38(3):541-54
pubmed: 23477736
Int J Gynaecol Obstet. 2010 Sep;110(3):199-202
pubmed: 20537326
Hum Immunol. 2018 Sep;79(9):693-701
pubmed: 29990511
Cancer Immunol Immunother. 2014 Jun;63(6):545-57
pubmed: 24658839
Reproduction. 2018 Aug 7;156(5):397-404
pubmed: 30087159
Proc Natl Acad Sci U S A. 2019 Nov 12;116(46):23132-23142
pubmed: 31666317
Cancer. 2005 Oct 1;104(7):1391-7
pubmed: 16116605
Mol Biol Int. 2014;2014:852748
pubmed: 25276427
Reprod Med Biol. 2018 Feb 01;17(3):220-227
pubmed: 30013421
Gynecol Oncol. 2014 Nov;135(2):364-70
pubmed: 25220628
Int J Gynecol Cancer. 2017 Oct;27(8):1701-1707
pubmed: 28683005
Cancer Treat Rev. 2014 Jul;40(6):770-80
pubmed: 24656976
Cancer Genet Cytogenet. 2004 Apr 15;150(2):144-52
pubmed: 15066322
Reprod Biol Endocrinol. 2018 Jun 21;16(1):60
pubmed: 29929546
Fertil Steril. 2012 Apr;97(4):997-1003
pubmed: 22306710
Mol Diagn Ther. 2013 Apr;17(2):85-99
pubmed: 23529353
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11918-23
pubmed: 20547831
Talanta. 2020 Mar 1;209:120574
pubmed: 31892056
Int J Tryptophan Res. 2017 Mar 15;10:1178646917691938
pubmed: 28469468
Mol Vis. 2014 Dec 23;20:1740-8
pubmed: 25593504
J Clin Endocrinol Metab. 2010 Dec;95(12):5320-9
pubmed: 20826587
Gynecol Oncol. 2018 Sep;150(3):569-580
pubmed: 29843906
Biochem Biophys Res Commun. 2012 Mar 16;419(3):490-4
pubmed: 22366088
Diabetes. 2010 Jan;59(1):249-55
pubmed: 19833897
Trends Endocrinol Metab. 2019 Mar;30(3):150-162
pubmed: 30712978
Br J Cancer. 2006 Dec 4;95(11):1555-61
pubmed: 17117179
Placenta. 2005 Jul;26(6):498-504
pubmed: 15950064
Int J Clin Exp Pathol. 2013;6(3):431-44
pubmed: 23411497
Front Immunol. 2018 Mar 02;9:208
pubmed: 29552006
Cell Biochem Biophys. 2013 Jul;66(3):843-50
pubmed: 23340902
J Pharmacol Exp Ther. 2009 Jul;330(1):89-98
pubmed: 19380603
Mod Pathol. 2018 Aug;31(8):1282-1290
pubmed: 29559741
Humangenetik. 1974 Jan 22;21(1):55-8
pubmed: 4134931